Compare MKS Instruments (MKSI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MKS Instruments vs Natera Inc. Common Stock — how do they compare? MKS Instruments trades at $230.19 (market cap $16.74B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.4× MKS Instruments's market cap, and MKS Instruments pays a 0.4% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MKS Instruments for 9 Days and Natera Inc. Common Stock for 0 Days on average.
| MKSI | NTRA | |
|---|---|---|
Market Cap | $16.74B | $57.03B |
Volume | 1,685,097 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $444.80 | $425.64 |
52-Week Low | $134.42 | $179.42 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $20.31B | $56.18B |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKSI trades at $247.56, down 0.94% on the day, with a bearish technical signal despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $3.30 exceeding expectations by 13.4%. Revenue growth continues with 2026 projections showing $4.3B and net profit margin expanding to 10.09%. Analyst consensus remains strongly bullish with 82.8% buy ratings and a $404 price target representing 63% upside potential.
The stock presents compelling growth potential driven by earnings momentum and institutional confidence, though near-term technical weakness and margin pressures from facility expansions pose risks. Long-term wafer fabrication equipment demand and ESG initiatives provide strategic tailwinds, but investors should monitor execution on profitability targets amid competitive pressures in the electronics sector.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MKS Instruments
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
